Identification of Circular RNAs as Biomarker Candidates in Lung Cancer Treatment

Volume 25, Issue 6, June 2024, Pages 2147-2157

Busra Apaydin; Ufuk Mert; Milad Asadi; Can Muftuoglu; Ayse Caner

• View Article
• PDF 777.99 K

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours

Volume 20, Issue 8, August 2019, Pages 2415-2420

Chen Yue-Yun; Hong Ye; Fu Yang; Li Qing; Lin Pan-Pan; Ding Zhen-Yu

• View Article
• PDF 508.35 K

A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit

Volume 19, Issue 10, October 2018, Pages 2973-2978

Adnan Khosravi; Babak Salimi; Zahra Esfahani-Monfared; Sharareh Seifi; Hanifeh Mirtavoos-Mahyari

• View Article
• PDF 501.53 K

Pemetrexed in Treating Patients with Metastatic Bladder Cancer

Volume 16, Issue 9, September 2015, Pages 3839-3841

• View Article
• PDF 333.76 K

Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549

Volume 16, Issue 4, April 2015, Pages 1507-1513

• View Article
• PDF 1.1 M

Pemetrexed is Mildly Active with Good Tolerability in Treating Patients with Gastric Cancer

Volume 15, Issue 17, December 2014, Pages 7137-7139

• View Article
• PDF 329.25 K

A Predictive Model for Evaluating Responsiveness to Pemetrexed reatment in Patients with Advanced Colorectal Cancer

Volume 15, Issue 14, December 2014, Pages 5941-5944

• View Article
• PDF 371.22 K

A Systemic Analysis on Pemetrexed in Treating Patients with Breast Cancer

Volume 15, Issue 11, November 2014, Pages 4567-4570

• View Article
• PDF 347.95 K

Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis

Volume 15, Issue 8, August 2014, Pages 3419-3424

• View Article
• PDF 644.4 K

Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer

Volume 15, Issue 8, August 2014, Pages 3447-3450

• View Article
• PDF 476.08 K

Pemetrexed as a Component of First-, Second- and Thirdline Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma

Volume 14, Issue 11, November 2013, Pages 6663-6667

• View Article
• PDF 437.06 K

Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy

Volume 14, Issue 5, May 2013, Pages 2703-2706

• View Article
• PDF 389.24 K

Potential Predictors of Sensitivity to Pemetrexed as First-lineChemotherapy for Patients with Advanced Non-SquamousNSCLCs

Volume 14, Issue 3, March 2013, Pages 2005-2008

• View Article
• PDF 413.77 K

Phase II Study of Pemetrexed as Second or Third LineCombined Chemotherapy in Patients with Colorectal Cancer

Volume 14, Issue 3, March 2013, Pages 2019-2022

• View Article
• PDF 347.62 K

Phase II Trial of Loubo® (Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or Taxanes

Volume 14, Issue 1, January 2013, Pages 413-417

• View Article
• PDF 422.62 K

Comparison of the Efficacy and Safety of EFGR TyrosineKinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

Volume 13, Issue 10, October 2012, Pages 5177-5182

• View Article
• PDF 575.91 K